Quadrivio one the leading private equity funds in Italy with more than €1 Bln of assets under management, has announced the launch of its second fund called TTVenture Due with a target of €100M which will invest in highly innovative and technological startups in the Life Sciences, Healthcare, Cleantech and New Materials space. The new TTVenture Due fund will be successor of Quadrivio's first fund TTVenture which launched in 2008 with a target of €64 million has been subscribed by the major italian banking fondations such as Fondazione Cariplo, Fondazione Cassa di Risparmio di Cuneo, Fondazione Cassa dei Risparmi di Forlì, Fondazione Cassa di Risparmio di Modena, Fondazione Cassa di Risparmio di Parma, Fondazione Cassa di Risparmio della Provincia di Teramo, Fondazione Cassa di Risparmio dell’Aquila, Fondazione Cassa di Risparmio di Ascoli Piceno, State Street Global Advisors and Camera di Commercio di Milano.
In its six years of operation, the first TTVenture fund has made 23 investments in innovative startups across different sectors mainly in the life sciences, medtech, new materials, cleantech, agri-food and industrial technology. Aim, Biouniversa, Bluegreen, Cogisen, CryptoLab, Directa Plus, D-Orbit, Eucardia, Glomeria Therapeutics, IpadLab, M31, MilkyWay, Pilegrowth Tech, Personal Factory, SanSeverino, Sem+, TTSeed and TTAdvisor are the innovative startups that benefted from the investment of the first TTVenture fund. The first TTVenture fund which was managed by fund Fondamenta SGR did also invest in four international funds such as Sofimac Partners (France - biotech), Terra Venture Partners (Israel - clean technologies and renewables), AXON Partners Group (Spain - material sciences) and Vertis (Southern Italy - digital technolgies. In 2012 was acquired by Quadrivio sgr when Fondamenta SGR became a subsidiary of Quadrivio.